Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates

Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberoi, Honey K., Garralda, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
CCR Translations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306344/
https://www.ncbi.nlm.nih.gov/pubmed/34135020
http://dx.doi.org/10.1158/1078-0432.CCR-21-1353
_version_ 1784752518738214912
author Oberoi, Honey K.
Garralda, Elena
author_facet Oberoi, Honey K.
Garralda, Elena
author_sort Oberoi, Honey K.
collection PubMed
description Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile. See related article by Johnson et al., p. 4521
format Online
Article
Text
id pubmed-9306344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93063442023-01-05 Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates Oberoi, Honey K. Garralda, Elena Clin Cancer Res CCR Translations Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile. See related article by Johnson et al., p. 4521 American Association for Cancer Research 2021-08-15 2021-06-16 /pmc/articles/PMC9306344/ /pubmed/34135020 http://dx.doi.org/10.1158/1078-0432.CCR-21-1353 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.
spellingShingle CCR Translations
Oberoi, Honey K.
Garralda, Elena
Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
title Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
title_full Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
title_fullStr Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
title_full_unstemmed Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
title_short Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates
title_sort unmasking new promises: expanding the antigen landscape for antibody–drug conjugates
topic CCR Translations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306344/
https://www.ncbi.nlm.nih.gov/pubmed/34135020
http://dx.doi.org/10.1158/1078-0432.CCR-21-1353
work_keys_str_mv AT oberoihoneyk unmaskingnewpromisesexpandingtheantigenlandscapeforantibodydrugconjugates
AT garraldaelena unmaskingnewpromisesexpandingtheantigenlandscapeforantibodydrugconjugates

Ejemplares similares